Related Experiment Video
Updated: Dec 8, 2025

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
Published on: June 20, 2025
Relationship Between Anemia and Sudden Cardiac Death in Patients With Severe Aortic Stenosis
Allison Ducharme-Smith1, C Anwar A Chahal2, Hiroyiku Sawatari3
1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Insights
Anemia is common in severe aortic stenosis (AS) and independently increases the risk of death and sudden cardiac death (SCD). Addressing anemia may improve outcomes for AS patients.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Severe aortic stenosis (AS) poses significant mortality risks, including sudden cardiac death (SCD).
- Anemia is a recognized risk factor for mortality in patients with AS.
Purpose of the Study:
- To investigate the prognostic impact of anemia on sudden cardiac death (SCD) in patients with severe aortic stenosis (AS).
- To determine if anemia is an independent predictor of mortality in severe AS.
Main Methods:
- Analysis of the Mayo Clinic AS database (n=7,292) with severe AS, excluding multiple valvular abnormalities.
- Survival and cause of death data were collected via the National Death Index and medical records.
- Multivariate analysis adjusted for multiple clinical factors to assess the association of anemia with mortality and SCD.
Main Results:
- Anemia (hemoglobin <13.0g/dl for men, <12.0 g/dL for women) was present in 40% of severe AS patients.
- Anemia was independently associated with increased all-cause mortality (HR 1.75) and increased SCD mortality (HR 1.42).
- During a median follow-up of 4.4 years, 10-year survival was 38% and 10-year SCD incidence was 5%.
Conclusions:
- Anemia is a frequent comorbidity in severe AS patients.
- Anemia independently predicts higher all-cause mortality and sudden cardiac death in severe AS.
- Anemia represents a potential prognostic marker and a modifiable therapeutic target in severe AS management.
Abstract:
Aortic stenosis (AS) is associated with significant morbidity and mortality, including sudden cardiac death (SCD). Anemia is a known risk factor for mortality in patients with AS. We sought to understand the prognostic implications between anemia and SCD in severe AS. The Mayo Clinic AS database includes 8,357 adults with severe AS (mean gradient ≥40 mm Hg, aortic valve area ≤1 cm2, or peak aortic jet velocity ≥4 m/s) enrolled between January 1, 1995 and April 30, 2015. Survival and cause of death were ascertained from the National Death Index and SCD from medical records. We excluded patients with multiple valvular abnormalities, leaving 7,292 subjects. The median (interquartile range, [IQR]) age was 76 (68, 82) years with 56% male, and median (IQR) hemoglobin level was 12.9 (11.6, 14.1) g/dl. The frequency of anemia (hemoglobin <13.0g/dl for men, <12.0 g/dL for women) was 40%. During median (IQR) follow up of 4.4 (1.8, 8.1) years, 4,056 died (10-year survival 38%) including 225 with SCD (10-year cumulative incidence 5%). In a multivariate model including age, sex, body-mass index, hypertension, diabetes mellitus, myocardial infarction, estimated glomerular filtration rate, and time dependent aortic valve replacement, anemia was associated with increased all-cause mortality (hazard ratios 1.75, 95%CI 1.64, 1.87; p < 0.001) and increased SCD mortality (hazard ratios 1.42, 95%CI 1.07, 1.86; p = 0.01). In conclusions, anemia is a frequent finding in patients with severe AS and independently associated with increased all-cause mortality and SCD. Anemia may be a useful prognostic marker and a modifiable therapeutic target in managing patients with severe AS.
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Aortic Regurgitation I: Introduction
Introduction Cardiac Emergencies
Mitral Stenosis I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Aortic Regurgitation III: Medical Management

